Wells Fargo analyst Derek Archila lowered the firm’s price target on Kezar Life Sciences (KZR) to $9 from $11 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR).
Education
About Us
Working with TipRanks
Follow Us
1